Ignite Creation Date:
2024-05-06 @ 3:48 PM
Last Modification Date:
2024-10-26 @ 1:57 PM
Study NCT ID:
NCT04765826
Status:
UNKNOWN
Last Update Posted:
2021-02-23
First Post:
2021-02-18
Brief Title:
Comparison Between Systemic Steroids Topical Steroids or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo
Sponsor:
Alexandria University
Organization:
Alexandria University
Study Overview
Official Title:
Comparison Between Systemic Steroids Topical Steroids or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study to compare the outcomes of mini punch grafting in patients with resistant stable non-segmental vitiligo already on narrowband ultraviolet B and receiving either no additional medication systemic mini pulse high and low dose steroids topical superpotent steroids once every other day or daily tacrolimus ointment in terms of the extent of repigmentation frequency of reactivation and side effects
Detailed Description:
Vitiligo a depigmenting skin disorder is characterized by the selective loss of melanocytes which in turn leads to pigment dilution or loss in the affected areas of the skin Vitiligo reportedly affects 05 to 2 of the worlds population without a clear preference for race or sex Vitiligo is clinically classified into two main clinical patterns nonsegmental and segmental Dermoscopy facilitates the diagnosis of vitiligo and can be used to assess the evolution of the stage of the disease stability progression repigmentation as well as the response to treatment Stability of vitiligo refers to the arrest of disease activity in terms of the absence of new lesions no extension of pre-existing lesions and an absence of Koebners phenomenon among other features The duration of stability is a matter of debate ranging from as little as six months to as long as two years Recent studies have indicated that skin lesions observed in vitiligo tend to recur in the same places where they were found before treatment This phenomenon is explained by the presence of a recently described subset of memory T cells known as cluster of differentiation CD8 resident memory T cells TRM in lesional vitiligo patient skin and a role in disease maintenance and relapse following treatment has been suggested Thus the use of immunosuppressantsmodulators could ameliorate their activity hence playing a role in stabilizing or treating the disease They could also improve the results of surgical options utilized in stable vitiligo refractory to medical treatments including tissue grafts full-thickness punch split-thickness and suction blister grafts cellular grafts autologous melanocyte cultures and non-cultured epidermal cellular grafts In addition to cultured epidermal suspensions and hair follicle transplantation These immune-modulators include systemic and topical corticosteroids a topical calcineurin inhibitor and phototherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None